We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Statin Cessation after Stroke Raises Recurrence Risk

By HospiMedica International staff writers
Posted on 17 Aug 2017
Discontinuing statin therapy three to six months after an initial ischemic stroke is tied to higher risk of a recurrent stroke, according to a new study.

Researchers at Chang Gung University College of Medicine (Taoyuan City, Taiwan), the Medical University of South Carolina (MUSC; Charleston, USA), and other institutions conducted a Taiwanese nationwide cohort study in order to explore the effects of statin discontinuation or statin dose reduction on recurrent stroke risk. More...
The source population comprised 45,151 ischemic stroke patients who were prescribed a statin within 90 days of discharge after an ischemic stroke between 2001 and 2012. There were 2,120 recurrent strokes during the study period.

The researchers found that during the day-90 to day-180 period, 7% were on reduced statin therapy, and 18.5% were not on any statin therapy. When compared to patients who maintained statin intensity therapy, discontinuation of statins was associated with a 42% increased risk of recurrent stroke, but maintaining a reduced-statin dose was not associated with additional risk. While age, ischemic heart disease, stroke history before index stroke, heart failure, and stroke severity index varied among the three groups, potential complications that could lead to statin discontinuation or reduction. The study was published on August 2, 2017, in the Journal of the American Heart Association.

“Stroke patients no longer on statins beyond the initial period following their index event had increased rates of recurrent stroke and death during the first year after statin discontinuation,” concluded lead author Meng Lee, MD, of Chang Gung University College of Medicine, and colleagues. “These findings suggest that providers and atherosclerotic stroke patients should not discontinue statin therapy unless there is a highly compelling reason for doing so.”

Statins lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. Several mechanisms may explain the harmful effect of statin discontinuation following stroke. First, statins stabilize plaques in arteries supplying brain and heart, reducing the risk of recurrent cerebral infarction and coronary artery disease (CAD) related events. Second, statin cessation has been associated with reduced flow‐mediated vasodilation, increased atrial fibrillation (AF), and elevated C‐reactive protein serum levels.

Related Links:
Chang Gung University College of Medicine
Medical University of South Carolina

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mobile X-Ray System
K4W
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.